top of page

Nestle invests $145m in biopharmaceutical firm Aimmune Therapeutics

Nestle Health Science is investing $145m for a 15% stake in Aimmune Therapeutics, a clinical-stage biopharmaceutical firm which develops treatments for people with life-threatening food allergies.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page